abiomed inc medical device technology company operates standalone business within johnson johnsons medtech abiomed develops manufactures temporary external implantable mechanical circulatory support devices company headquartered danvers massachusetts additional offices woburn baltimore berlin aachen tokyo andrew greenfield president company dr thorsten siess executive vice president chief technology officer dr chuck simonton executive vice president chief medical according bloomberg company engages research development sale medical devices assist replace pumping function failing heart also provides continuum care heart failure company secured five fda approvals patents fiscal year abiomed reported billion revenue reported diluted earnings per share december johnson johnson completed acquisition abiomed founded danvers massachusetts david lederman applied biomedical year company commenced development artificial funded federal research lederman partnered texas heart institute develop abiocor grapefruitsized electromagnetic device internal battery completely replaces heart without wires tubes passing july abiocor became first artificial heart successfully implanted patient pumped million fourteen abiocor devices implanted clinical trials longestliving recipient surviving abiocor fda approval patients near death qualify heart michael r minogue became president ceo abiomed purchased ventricular assist device company impella cardiosystems ag aachen maker impella heart pump developed thorsten chief technology officer source abiomed acquired impella companys focus shifted heart replacement heart july abiomed acquired german heart pump maker ecp deal worth million deal included nearly million buyout ais gmbh aachen innovative solutions owns patents licensed may abiomed added sp sps rise abiomed indexs top performing abiomed built million innovation center facilitate research product development headquarters facility features laboratories blood optical software mechanical electrical research plus production barrons ranked abiomed fourth best stock total return fortune ranked abiomed magazines list fastestgrowing april abiomed acquired medical device company breethe startup spun university startup developed portable extracorporeal membrane oxygenation ecmo system acts like artificial lung oxygenating removing carbon dioxide blood patient cardiogenic shock respiratory technology known abiomed breethe system received fda clearance later june abiomed appointed charles simonton md vice president chief medical also fda granted emergency use authorization impella heart pump stabilize patients following removal pulmonary blood clots well use impella combination breethe extracorporeal membrane oxygenation ecmo system pumps oxygen february april abiomed appointed neurosurgeon myron rolle cardiologist paula johnson board drs rolle johnson serve governance nominating committee regulatory compliance committee june abiomed acquired precardia catheter developer whose system allows lessinvasive option treating acute decompensated heart failure adhf november abiomed announced would acquired johnson johnson billion deal closed december following acquisition abiomed continues operate standalone business within johnson johnsons medtech impella worlds smallest heart sits heart spinning revolutions per minute sending blood throughout body allowing heart rest recover inserted minimally invasive procedure guided artery impella heart pump among healthcare products receive medical design excellence impella heart pump products include impella impella impella cp smartassist impella smartassist impella rp smartassist impella connect gives providers secure access impella status data cloud impellasupported abiomed breethe system extracorporeal membrane oxygenation ecmo system pumps oxygenates removes carbon dioxide blood patients suffering cardiogenic shock respiratory failure due ards sars among causes used alone conjunction impella heart since abiomed acquired impella heart devices received series fda notably abiomed received fda approval use impella heart pump elective urgent highrisk percutaneous coronary intervention procedures fda approval based protect ii randomized controlled trial found highrisk percutaneous coronary intervention pci patients underwent pci impella fewer major adverse events days although statistically nonsignificant compared patients underwent pci intraaortic balloon pump impella rp system became first percutaneous singleaccess heart pump designed rightheart support receive fda lack data randomized controlled trials impella devices cardiogenic shock despite calls medical early studies suggested short term benefits propensitymatched analyses comparing impella device intraaortic balloon pump iabp showed benefit clinically relevant outcomes may partly due increased risk bleeding peripheral vascular complications impella studies even suggested increased risk mortality impella devices compared intraaortic balloon pump iabp additional expense currently adequately powered randomized controlled trials impella device clinically relevant outcomes mortality fda granted premarket approval impella rp smartassist first singleaccess dualsensor technology device provide temporary percutaneous ventricular support patients acute right heart failure decompensation implanting left ventricular assist device myocardial infarction heart transplant openheart fda also granted breakthrough device designation smallest heart pump impella ecp measures april abiomeds impella bridgetorecovery btr minimallyinvasive heart pump successfully implanted first patient treated device part early feasibility august results restore ef study published journal society cardiovascular angiography interventions study demonstrated impellasupported highrisk percutaneous coronary intervention pci led significant improvements left ventricular ejection fraction lvef angina symptoms heart failure symptoms october fda granted premarket approval impella rp flex smartassist treatment acute right heart failure andrew greenfield abiomeds president since company acquired johnson johnson december succeeded michael r minogue retired serving chairman president ceo since abiomeds founder david lederman stepped httpsenwikipediaorgwikiabiomed